Paige.AI, a a NYC-based start-up advancing clinical diagnosis and treatment in oncology through use of artificial intelligence (AI), raised $25m in Series A funding.
Among the lead investors is Jim Breyer, founder and chief executive officer of Breyer Capital, a premier global venture capital firm based in Menlo Park, California.
Led by Thomas Fuchs, PhD and David Klimstra, MD, Paige.AI will develop computational solutions across diagnostic pathology, initially focusing on clinical applications in breast, prostate and other major cancers.
The company signed a comprehensive license agreement with Memorial Sloan Kettering Cancer Center (MSK) to gain exclusive access to MSK’s intellectual property in the field of computational pathology, as well as exclusive rights to MSK’s library of 25 million pathology slides.
Paige.AI also expects to partner with other leading academic medical centers, commercial labs and pharmaceutical companies as it develops a full suite of AI applications in pathology.